NCT04199715View on ClinicalTrials.gov

Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

January 20, 2022

Study Completion Date

January 20, 2022

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Heplisav-B

This is an FDA-approved vaccine for Hepatitis B that is made by Dynavax Technologies.

Trial Locations (1)

75246

Baylor Scott & White Research Institute, Dallas

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER